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Invasion and metastasis define malignancy and are major causes
of cancer mortality. Tumour metastasis is a complex multistep
process that involves invasion of the surrounding tissues through
the confining basement membrane, penetration of blood or
lymphatic vessels (intravasation), and exiting vessels at distant
sites (extravasation) to form secondary tumours (Liotta and
Stetler-Stevenson, 1991; Kohn and Liotta, 1995). Since extracel-
lular matrix (ECM) and basement membrane components provide
the main physical barriers against tumour cell invasion, proteolytic
degradation of these structures is a critical step for invasion and
metastasis (Liotta et al, 1986; Stetler-Stevenson et al, 1993).
Among the enzymes involved in this degradation are the metallo-
proteinases (MMPs), a family of Zn2+-dependent endopeptidases
produced by host and tumour cells (Matrisian, 1990; Woessner,
1991) that include interstitial collagenase (MMP-1), gelatinase A
(MMP-2, 72-kDa gelatinase or type IV collagenase), gelatinase B
(MMP-9, 92-kDa gelatinase or type IV collagenase), and
stromelysin (MMP-3). MMP-2 and MMP-9 are of particular
importance in tumour cell invasion, because they can degrade type
IV collagen, the main structural component of the basement
membrane (Liotta et al, 1986). It has been shown that tumour cells
expressing high levels of these enzymes are highly metastatic
(Liotta et al, 1980; Nakajima et al, 1987; Murphy et al, 1989;
Streenath et al, 1992; Bernhard et al, 1994).
The activity of MMPs is regulated at various stages, including
transcription, secretion, proenzyme activation and inhibition by
tissue inhibitors of metalloproteinases (TIMPs) (Matrisian, 1990;
Liotta et al, 1991; Woessner, 1991). To date, four TIMPs, encoded
by four distinct genes, have been identified: TIMP-1 (Carmichael
et al, 1986), TIMP-2 (DeClerck et al, 1989; Goldberg et al, 1989;
Stetler-Stevenson et al, 1989), TIMP-3 (Pavloff et al, 1992), and
TIMP-4 (Lew et al, 1997). Several studies have demonstrated that
TIMP-1 and TIMP-2 play an important role in preventing tumour
cell invasion and metastasis (Albini et al, 1991; DeClerck et al,
1991, 1992; Porto et al, 1991; Montgomery et al, 1994). Other
studies have, however, shown a complex relationship between
TIMPs and tumour invasiveness. Elevated TIMP-1 or TIMP-2
expression was found to be correlated with the extent of tumour
cell invasion in non-Hodgkin￿s lymphoma (Kossakowska et al,
1991), gliomas (Nakano et al, 1995), colon (Lu et al, 1991) and
breast carcinomas (Visscher et al, 1994).
It is not known whether TIMP-1 plays a role in thyroid tumour
invasion and metastasis. In the present study, we therefore investi-
gated TIMP-1 gene expression in 39 primary thyroid tumours to
see whether there is a correlation between TIMP-1 expression and
the aggressiveness of the disease. We also transfected human
TIMP-1 cDNA into a papillary thyroid carcinoma cell line (NPA)
to study the effect of TIMP-1 expression on its invasive potential
using an in vitro tumour invasion assay.
MATERIALS AND METHODS
All tumour specimens were obtained at surgery and were immedi-
ately frozen in liquid nitrogen and stored at —70°C until processed.
The clinical staging of thyroid tumours was based on the TNM
classification introduced in 1987 by the International Union
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45 years and over: stage 1 — microcarcinoma (< or = 1 cm) without
lymph node involvement; stage 2 — tumours (> 1 cm) confined to
the thyroid without lymph node involvement; stage 3 — any T-stage
with lymph node involvement or tumours with invasion of peri-
thyroidal tissue; stage 4 — distant metastasis and anaplastic
tumours; for patients under 45 years: stage 1 — any T-stage with or
without lymph node involvement; stage 2 — distant metastasis. Six
multinodular goitres (adenomatous hyperplasia), 28 papillary
carcinomas, two follicular carcinomas and three anaplastic carci-
nomas were studied.
The human papillary thyroid carcinoma cell line, NPA, was
kindly provided by Dr James A Fagin, Division of Endocrinology
and Metablism, University of Cincinnati Medical Center,
Cincinnati, OH, USA, and the squamous thyroid carcinoma cell
line, SW579, was obtained from ATCC (Rockville, MD, USA).
The full-length human TIMP-1 cDNA probe was obtained 
from thyroid RNA by reverse transcription-polymerase chain 
reaction (RT-PCR) using the following primers (Carmichael et al,
1986): 5¢-CATCGCCGCAGATCCAGCGCCCAG-3¢ (sense), 5¢-
GGCTTCTGCTTCCACTCCGGGC-3¢ (anti-sense). The PCR
product was subcloned into a TA cloning vector (pTIMP-1/TA)
(Invitrogen Co., San Diego, CA, USA) and verified by DNA
sequencing.
The oligonucleotide probe for 18S ribosomal RNA was synthe-
sized and the sequence is as follows: 5¢-GGTCAGCGCTCGTCG-
GCATGTAATAG-3¢.
RNA extraction and Northern hybridization
Total RNA was extracted from thyroid tumour samples and cell
lines by the conventional guanidinium thiocyanate—phenol—
chloroform method (Chomczynski and Sacchi, 1987). Twenty
micrograms of total RNA were fractionated on a 1% agarose
gel containing 2.2 M formaldehyde and blotted onto a nylon
membrane (Hybond-N, Amersham) by capillary transfer. The
accuracy of RNA loading was monitored by ethidium bromide
staining of ribosomal RNA and later by hybridization to an oligo-
probe for 18S ribosomal RNA as previously described (Shi et al,
1991). The TIMP-1 cDNA probe was labelled with [a-32P]dCTP
to a specific activity of 109 cpm/mg using Pharmacia￿s random
primer labelling kit. Hybridization was performed at 42°C for 18 h
in 6 ´ SSPE, 10 mM EDTA, 5 ´ Denhardt￿s solution, 0.5% sodium
dodecyl sulphate, 100 mg ml—1 denatured salmon testis DNA, and
50% formamide. The membranes were then washed twice over
15 min in 2 ´ SSPE at 65°C and exposed to Kodak XAR-5 film
at —70°C with intensifying screens.
Following autoradiography, band intensity of TIMP-1 mRNA
was quantitated by a scanning densitometer (Bio-Rad model GS-
670) and normalized by comparison with the intensity of the 18S
ribosomal RNA band.
Immunohistochemical procedures
Tumours were frozen and stored at —70°C prior to embedding in
OCT compound. Sections (5 mm) cut from the frozen tissue blocks
were fixed in cold acetone for 10 min before staining. Slides were
then incubated with TIMP-1 monoclonal antibody (2 mg ml—1 in
phosphate-buffered saline) for 30 min at room temperature and
stained using mouse UniTect immunoperoxidase staining kit
according to the manufacturer￿s instructions (Oncogene Science
Inc., Cambridge, MA, USA). Mouse IgG from the kit was used as
negative control.
Construction of pTIMP-1/CMV vector
The pTIMP-1/TA was digested with Hind III and Xba I restriction
endonucleases to obtain TIMP-1 cDNA. The resulting fragment is
oriented such that the 5¢-end of the TIMP-1 cDNA is close to the
Hind III site. The Hind III/Xba I fragment was then ligated into
Hind III/Xba I sites of pRc/CMV, a eukaryotic expression vector
from Invitrogen Co. (San Diego, CA, USA). The construct
(pTIMP-1/CMV) was verified by DNA sequencing.
Transfection assay
NPA cells were cultured in F-12 medium with 10% fetal calf
serum, penicillin (100 U ml—1), streptomycin (100 mgm —1l), and
fungizone (25 mgm l —1) at 37°C in a humidified atmosphere
containing 5% carbon dioxide. Transfection was initiated when the
NPA cell culture was 70% confluent. Twenty micrograms of
pTIMP-1/CMV were transfected into the cells using calcium phos-
phate precipitation as described previously (Chen and Okayama,
1987). Seventy-two hours after transfection, 400 mgm l —1 G418
(Geneticin; Life Technologies Inc., Grand Island, NY, USA) were
added and the cells were cultured for 3 weeks to select stable trans-
fectants. Seven out of 200 surviving clones were characterized by
Northern blot analysis and two clones were selected for use in a
tumour invasion assay: TP-1 (high TIMP-1 expression), and TP-5
(low TIMP-1 expression). NPA cells transfected with the vector
(pRc/CMV) alone were used as a control.
In vitro tumour invasion assay
The invasion assay was performed to quantitate the relative degree
of invasiveness of pRc/CMV.NPA (control), TP-1, and TP-5
thyroid carcinoma cells, as described previously (Parhar et al,
1995). Briefly, 3 mm pore size filters in the so-called Transwell
insert (Costar, Cambridge, MA, USA) were coated with 25 ml of
basement membrane matrigel (1 mg ml—1) (collaborative research,
Bedford, MA, USA) and dried under a hood. The Transwell insert
was then placed in a Costar 24-well cluster plate. Sub-confluent
cultures were labelled for 30 h with 1 mCi ml—1 125I-deoxyuridine
(74 TBq mmol—1, Amersham, Aylesbury, UK). The cells were
trypsinized, washed and resuspended in complete F-12 medium.
Viable cells (2.5 ´ 105) were added to the upper compartment of
the chamber in a total volume of 0.5 ml medium. The lower
compartment of the chamber was filled with 0.5 ml of medium.
After incubation for 96 h at 37°C in a humidified atmosphere
containing 5% carbon dioxide, tumour cells that had migrated to
the lower surface of the filters were recovered with trypsin—EDTA
and counted in a gamma counter (1272 Clini gamma, Turku,
Finland). All experiments were performed in triplicate and
repeated three times.
Statistical analysis
The significance of difference between means was analysed by the
unpaired Student￿s t-test (two-tailed test). A value of P < 0.05 was
considered significant.
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RESULTS
TIMP-1 gene expression in thyroid tumour tissue
specimens
The abundance of TIMP-1 mRNA was examined in tissues from
six multinodular goitres and 33 malignant thyroid tumours. TIMP-
1 was expressed in all the tissues studied. Figure 1 shows Northern
blot hybridization results for a representative panel of tumour
specimens. The level of TIMP-1 expression was quantitated by a
densitometer and compared among tumours of different stages
(Figure 2 and Table 1). Multinodular goitres have a value of
2.60 ± 0.34 (mean ± SEM); stage I differentiated thyroid carci-
nomas, 4.27 ± 0.62; stage II, 3.95 ± 1.18; stage III, 6.49 ± 0.73; and
stage IV, 7.40 ± 0.27. Anaplastic carcinomas have a value of
7.50 ± 0.44. Therefore, TIMP-1 expression started to increase in
the early stage of thyroid carcinoma (stage I) as compared with
that in benign multinodular goitres (t = 2.56, P < 0.05) (Figure 1
and Table 1). A significant increase in TIMP-1 expression was
observed in samples with advanced stages of thyroid carcinoma
(stages III and IV) as compared to multinodular goitres (t = 6.91, P
< 0.0001) or stage I tumours (t = 2.75, P < 0.05). We also analysed
TIMP-1 expression in both NPA and SW579 cell lines which are
derived from poorly differentiated thyroid carcinomas.
Interestingly, TIMP-1 expression was not increased in either NPA
or SW579 cells as compared to multinodular goitres (Table 1). The
level of TIMP-1 expression and relevant clinical data on the
patients studied are summarized in Table 1.
In order to address the question of whether tumour cells or
stroma cells are the source of the increased TIMP-1 expression, we
performed immunohistochemical analysis of seven papillary carci-
noma specimens with increased TIMP-1 mRNA levels. All of
them demonstrated strong TIMP-1 immunostaining in the stroma
cells with no, or weak, tumour cell staining. A representative
immunohistochemical staining is shown in Figure 3.
Effects of TIMP-1 overexpression on the invasiveness
of NPA cells
The presence of high levels of TIMP-1 expression in advanced
stages of thyroid carcinoma prompted us to ask whether increased
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Figure 1 Northern blot analysis of TIMP-1 mRNA levels in 13 thyroid tumour
specimens. Twenty micrograms of total RNA were electrophoresed on an
agarose/formaldehyde gel and blotted onto a nylon membrane. Hybridization
was carried out with a full-length human TIMP-1 cDNA probe (upper panel),
and an oligoprobe for 18S ribosomal RNA to monitor the actual RNA loading
(lower panel). Goitre: lanes 1, 9; stage I thyroid cancer: lanes 5, 8; stage II
thyroid cancer: lanes 4, 6, 7; stage III thyroid cancer: lane 3; stage IV thyroid
cancer: lanes 2, 10–13. Samples 1–13 correspond to tumour specimens 1,
37, 11, 18, 35, 19, 20, 21, 2, 22, 38, 23 and 39, respectively, shown in Table 1
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Figure 2 Densitometric determination of the relative TIMP-1 mRNA levels.
TIMP-1 transcripts were quantitated densitometrically from Northern blots
and were expressed as density units relative to the signals obtained with the
18S rRNA probe. To allow comparisons among separate Northern blots, two
common samples were included on each blot and TIMP-1 signals were
normalized to the values obtained with these RNA samples. Values are
expressed as a mean ± SEM. (A) Multinodular goitre (n = 6); (B–E)
differentiated thyroid cancer stage I (n = 14), stage II (n = 6), stage III (n = 7)
and stage IV (n = 3), respectively, (F), anaplastic cancer (n = 3)
Table 1 TIMP-1 gene expression in thyroid tumours
Tumour Histology Stage Age Sex TIMP-1 expressiona
1 227889 Multinodular Goitre 31 F 3.2
2 216951 Multinodular Goitre 39 F 3.3
3 258127 Multinodular Goitre 35 M 2.4
4 280061 Multinodular Goitre 30 F 1.5
5 266427 Multinodular Goitre 40 F 1.8
6 186282 Multinodular Goitre 27 F 3.4
7 238533 Papillary Ca I 24 F 3.2
8 280331 Papillary Ca I 23 F 5.6
9 280499 Papillary Ca I 26 F 1.9
10 284942 Papillary Ca I 36 F 1.3
11 242132 Papillary Ca III 63 F 8.4
12 277092 Papillary Ca I 27 F 3.9
13 281524 Papillary Ca I 36 M 6.0
14 282201 Papillary Ca I 31 F 8.7
15 264860 Papillary Ca IV 68 F 6.9
16 285061 Papillary Ca I 21 F 4.0
17 285248 Papillary Ca I 24 F 1.6
18 243117 Papillary Ca I 35 F 5.5
19 150121 Papillary Ca III 45 F 4.6
20 291156 Papillary Ca I 40 F 8.2
21 259277 Papillary Ca I 23 F 3.9
22 158236 Papillary Ca IV 47 F 7.5
23 242029 Papillary Ca IV 70 F 7.8
24 230021 Papillary Ca III 59 F 8.8
25 260552 Papillary Ca I 25 F 3.9
26 272560 Papillary Ca III 60 M 6.1
27 292307 Papillary Ca III 70 F 3.5
28 278600 Papillary Ca III 46 M 7.4
29 294915 Papillary Ca I 32 F 2.1
30 286226 Papillary Ca III 58 F 6.6
31 023894 Papillary Ca II 47 F 1.6
32 284471 Papillary Ca II 41 F 8.8
33 296221 Papillary Ca II 72 F 5.9
34 258028 Papillary Ca II 52 F 3.0
35 178890 Follicular Ca II 48 F 1.5
36 224253 Follicular Ca II 56 F 2.9
37 287120 Anaplastic Ca IV 76 F 6.7
38 246240 Anaplastic Ca IV 81 M 7.6
39 219342 Anaplastic Ca IV 43 F 8.2
NPA 3.7
SW579 2.4
aTIPM-1 mRNA levels expressed as density units relative to signals obtained
with the 18S rRNA probe. M, male; F, female; Ca, carcinoma.TIMP-1 expression in thyroid carcinomas 1237
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TIMP-1 expression plays a role in counteracting the invasive
behaviour of thyroid carcinoma. Gene transfer was used to stably
express human TIMP-1 cDNA in a papillary thyroid carcinoma
cell line, NPA. Two clones were selected for use in the in vitro
invasion assay: one expressing high (TP-1), and the other low (TP-
5) levels of exogenous TIMP-1 transcripts (Figure 4). As shown in
Figure 5, high TIMP-1 expression decreased the invasiveness of
NPA cells. As compared to the control, the invasive potential of
TP-1 and TP-5 cells was reduced by 53% (t = 7.48, P < 0.0001)
and 35% (t = 4.86, P < 0.001), respectively. Therefore, higher
TIMP-1 expression was associated with increased inhibition of the
invasive potential of NPA cells (TP-1 vs TP-5, t = 2.23, P < 0.05).
DISCUSSION
The data presented herein show that TIMP-1 is expressed in both
benign and malignant thyroid tumours, and that higher TIMP-1
expression is associated with advanced disease stages (stages III
and IV). The findings seem to be contradictory to the proposed
role of TIMP-1 as a tumour metastasis suppressor: if TIMP-1 acts
as a functional inhibitor of tumour invasion and metastasis, its
expression should inversely correlate with the aggressiveness of
thyroid tumours. Indeed, such an inverse association has been
documented in several (Albini et al, 1991; DeClerck et al 1991,
1992; Ponto et al, 1991; Khoka et al, 1992, 1994; Montgomery et
al, 1994) but not all (Kussakowska et al, 1991; Lu et al, 1991;
Visscher et al, 1994a, 1994b; Nakana et al, 1995; Zeng et al, 1995;
Grignon et al, 1996) human and mouse tumours. One possible
explanation for increased TIMP-1 expression in advanced stages
of thyroid carcinoma is that it may represent a secondary event, i.e.
invasive tumour cells may produce MMPs, which may induce
surrounding stroma cells to produce TIMP-1 to contain tumour
cells that would be otherwise even more invasive. Although the
number of TIMP-1 transcripts is elevated, it may not be effective
in both quantity or possibly quality (enzymatic activity) in coun-
teracting MMPs produced by thyroid tumour cells. The high level
of TIMP-1 may, therefore, reflect stroma response to elevated
production of MMPs, and the imbalance between TIMP-1 and
MMPs activities would result in ECM destruction and tumour
invasion. A recent study by Soloway et al (1998) using targeted
mutagenesis of TIMP-1 further revealed that tumour invasion and
metastasis were influenced by TIMP-1 of the tumour and not of
the host. Thus, it is likely that TIMP-1 level within tumour cells
rather than in stroma cells determines their invasive behaviour.
The strong TIMP-1 immunostaining in stroma cells suggests
that the high levels of TIMP-1 transcripts in advanced stages of
thyroid carcinoma would likely represent a stroma response to
tumour cell invasion. This is supported by the low TIMP-1 expres-
sion in both NPA and SW579 thyroid cancer cell lines that are
derived from poorly differentiated thyroid carcinomas without
stroma contamination. Several studies have demonstrated that
A
B
Figure 3 Localization of TIMP-1 protein in an invasive thyroid papillary
carcinoma specimen by immunohistochemistry. Section was stained with
mAb against TIMP-1 using ABC immunoperoxidase staining system from
Oncogene Science Inc. Note the strong TIMP-1 immunoreactivity within the
stroma between the infiltrative tumour nests (magnification: (A) ´ 400; 
(B) ´ 200)
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Figure 4 TIMP-1 expression in transfected NPA thyroid carcinoma cell
clones. Northern blot hybridization of full-length human TIMP-1 cDNA probe
to 20 mg of total RNA extracted from human TIMP-1 transfected clones
(upper panel). The endogenous TIMP-1 transcript is 0.9 kb and the
transfected one is 1.1 kb which is indicated by an arrow. Lanes 1–3 represent
high TIMP-1 expression clone (TP-1), vector alone transfected clone
(control), and low TIMP-1 expression clone (TP-5), respectively. The actual
RNA loading was monitored by ethidium bromide staining of RNA loaded for
Northern blot analysis (lower panel)1238 Y Shi et al
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increased TIMP-1 or TIMP-2 expression in advanced stages of
malignancy derives predominantly from stroma cells rather than
from cancer cells themselves (Kossakowska et al, 1991; Visscher
et al, 1994b; Zeng et al, 1995; Grignon et al, 1996). In the study of
elevated TIMP-1 mRNA levels in non-Hodgkin￿s lymphoma,
Kossakowska et al (1991) showed by in situ hybridization that
TIMP-1 transcripts were not localized to the malignant lympho-
cytes, but instead were present within stromal cells which account
for only 20% of the total cells in each sample. Similar results were
observed by Zeng et al (1995) in colorectal cancer. These investi-
gators found that TIMP-1 mRNA was present predominantly in
tumour stroma within spindle fibroblast-like cells. In invasive
bladder and breast cancers, elevated TIMP-2 was mostly localized
by immunohistochemistry in the tumour stroma around nests of
invasive tumour cells (Visscher et al, 1994b; Grignon et al, 1996).
In order to determine whether TIMP-1 suppresses thyroid
tumour cell invasion through basement membranes, we transfected
NPA cells with human TIMP-1 cDNA and isolated clones with
high and low TIMP-1 expression. Their invasive potentials were
assessed by an in vitro tumour invasion assay in which reconsti-
tuted basement membranes (Matrigel¤) were used. One major
advantage of the system is that it allows quantitative analysis of
the invasive activity of tumour cells, even though Matrigel¤ lacks
the structural organization of the intact basement membranes
(Albini et al, 1987; Hendrix et al, 1987). The assay measures the
capability of a given tumour cell to attach to, degrade, and finally
pass through, the matrix. These events are considered to be impor-
tant steps in tumour cell invasion through basement membranes in
vivo. In the present study, we demonstrated that NPA cells with
high TIMP-1 expression were less invasive than those with low
TIMP-1 level. The data suggest that TIMP-1 may indeed play an
inhibitory role in thyroid tumour invasion and metastasis. Whether
the expression of TIMP-1 from tumour vs stroma cells makes a
difference in this regard is not known and requires further studies.
In summary, we have found elevated TIMP-1 mRNA in
advanced stages of thyroid carcinoma. The increased levels of
TIMP-1 transcripts likely come from stroma cells as an attempt to
counteract tumour invasion and metastasis. NPA cells expressing
high TIMP-1 transcripts have significantly less invasive potential
in vitro than those with low TIMP-1 expression, supporting the
role of TIMP-1 as a metastasis suppressor.
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